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Clumping factor B (ClfB) of Staphylococcus aureus binds to cytokeratin 10 and to fibrinogen. In
this study the binding site in human fibrinogen was localized to a short region within the C
terminus of the Aa-chain. ClfB only bound to the Aa-chain of fibrinogen in a ligand-affinity blot and
in solid-phase assays with purified recombinant fibrinogen chains. A variant of fibrinogen with
wild-type Bb- and c-chains but with a deletion that lacked the C-terminal residues from 252–610
of the Aa-chain did not support adherence of S. aureus Newman expressing ClfB. A series of
truncated mutants of the recombinant Aa-chain were tested for their ability to support adherence
of S. aureus Newman ClfB
+, which allowed the binding site to be localized to a short segment of
the unfolded flexible repeated sequence within the C terminus of the Aa-chain. This was
confirmed by two amino acid substititions within repeat 5 of the recombinant Aa-chain which did
not support adherence of Newman ClfB
+. Lactococcus lactis expressing ClfB mutants with
amino acid substitutions (N256 and Q235) located in the putative ligand-binding trench between
domains N2 and N3 of the A-domain were defective in adherence to immobilized fibrinogen and
cytokeratin 10, suggesting that both ligands bind to the same or overlapping regions.
INTRODUCTION
Staphylococcus aureus is an important opportunistic
pathogen of humans that is responsible for a wide range
of infections ranging from superficial skin infections to
more serious invasive diseases such as endocarditis,
osteomyelitis and septicaemia. The primary habitat of S.
aureus is the moist squamous epithelium of the anterior
nares (Cole et al., 2001; Peacock et al., 2001). The success of
S. aureus as a pathogen is due in part to its ability to adhere
to a wide range of host tissues including host extracellular
matrix proteins such as fibrinogen (Fg), fibronectin and
collagen. Adhesion to host proteins is mediated by bacterial
cell-wall-associated proteins called MSCRAMMs (micro-
bial surface components recognizing adhesive matrix
molecules). S. aureus can express up to 20 different
potential MSCRAMMs that are covalently anchored by
sortase to peptidoglycan (Mazmanian et al., 1999; Navarre
& Schneewind, 1994).
S. aureus expresses several different proteins that can bind
specifically to Fg, including clumping factors A and B (ClfA
and ClfB) and the bifunctional fibronectin- (and Fg-)
binding proteins A and B, FnbpA and FnbpB (McDevitt
et al., 1994; Ni Eidhin et al., 1998; Perkins et al., 2001;
Wann et al., 2000). ClfA, FnbpA and FnbpB bind to the
extreme C terminus of the c-chain protruding from
domain D of Fg. In contrast, the SdrG protein from
Staphylococcus epidermidis binds to the fibrinopeptide-B
protruding from domain E (Davis et al., 2001). S. aureus
also secretes several proteins that bind Fg, notably
coagulase, the extracellular Fg-binding protein (Efb) and
MHC class II analogue protein (Map) (Jonsson et al., 1995;
McGavin et al., 1993; Palma et al., 1998; Phonimdaeng
et al., 1990).
ClfB is only expressed on the cell surface during the
exponential phase of growth (McAleese et al., 2001).
Ligand binding is specified by the A region, which is
divided into three independently folded subdomains N1,
N2 and N3 (Perkins et al., 2001). The S. aureus
metalloprotease aureolysin cleaves ClfB between N1 and
N2, resulting in the loss of Fg-binding activity at the end of
the exponential phase of growth (McAleese et al., 2001;
Perkins et al., 2001). ClfB is a bifunctional MSCRAMM. It
binds to cytokeratin 10 (CK10) exposed on the surface of
desquamated epithelial cells in addition to Fg. It is a major
determinant of the ability of S. aureus to adhere to
squamous cells and to colonize the anterior nares (O’Brien
et al., 2002). The binding domain in CK10 was shown to be
quasi-repeats of glycine and serine residues that occur as
Abbreviations: CK10, cytokeratin 10; Fg, fibrinogen; HRP, horseradish
peroxidase; MSCRAMMs, microbial surface components recognizing
adhesive matrix molecules.
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which likely protrude from keratin filaments (Walsh et al.,
2004).
Fg is a 340 kDa plasma protein that plays a crucial role in
haemostasis. It is composed of two identical disulfide-
linked subunits, each of which is composed of three non-
identical polypeptide chains, Aa,B b and c (Doolittle, 1984;
Henschen & MCDonagh, 1986; Herrick et al., 1999). The
removal of C termini of the Aa-chains (residues 220–610)
by proteolysis results in generation of aC fragments,
representing the whole or parts of the aC-domain
(Weisel & Medved, 2001). The aC-domains are involved
in fibrin assembly and clot formation (Cierniewski &
Budzynski, 1992; Gorkun et al., 1994; Medved et al., 1985)
and control activation of factor XIII (Credo et al., 1981).
The aC-domains and the N-terminal portions of the Bb-
chains are the parts of the Fg molecule for which the 3D
structure has not been established (Yang et al., 2001).
However, recent studies have shown that the aC-domain
consists of two structurally distinct regions, a flexible
connector region from residues 221–391 and an indepen-
dently folded, compact portion from residues 392–610
(Fig. 1) (Burton et al., 2006; Tsurupa et al., 2002). In
human Fg the flexible NH2-connector region is unordered
and is composed of a 43-residue segment followed by ten
13-residue tandem repeats.
In this study we investigated the binding of ClfB to human
Fg and have localized the binding site to one of the tandem
repeats within the flexible connector region of the aC-
domain.
METHODS
Bacterial strains and growth conditions. Escherichia coli strain
XL-1 Blue was used as the host for plasmid cloning and was routinely
grown in L-broth or agar with ampicillin (100 mgm l
21) and
tetracycline (10 mgm l
21) as appropriate. Strain TOPP3 (Stratagene)
was used as the host for recombinant ClfB A-domain (rClfB 45–542)
or rClfA A-domain (rClfA 221–559) protein expression. E. coli strain
JM101 was used for expression of recombinant Fg proteins.
The S. aureus strains are mutants of strain Newman (Duthie &
Lorenz, 1952) defective in ClfA (DU5876 clfA2::Tn917) (McDevitt et
al., 1994) and a double mutant defective in ClfA and ClfB (DU5944
clfA2::Tn917 clfB::Tc
r) (Ni Eidhin et al., 1998). Bacteria were
routinely cultured in trypticase soy broth or on agar. For optimum
expression of ClfB, S. aureus was grown to exponential phase (OD600
0.6) in 50 ml brain heart infusion broth in a 250 ml conical flask
shaken at 200 r.p.m. at 37 uC (McAleese et al., 2001; Ni Eidhin et al.,
1998).
Lactococcus lactis strain NZ9800 carrying the nisin-inducible expres-
sion plasmid pNZ8037 expressing clfB or clfB Q235A was described
previously (Miajlovic et al., 2007). L. lactis pNZ8037clfB N526A was
constructed by site-directed mutagenesis as described for L. lactis
pNZ8037clfB Q235A (Miajlovic et al., 2007) using the primers shown
in Table 1. L. lactis strains were grown statically at 28 uC in M17
(Difco) broth incorporating 0.5% (w/v) glucose, chloramphenicol
(Sigma, 10 mgm l
21) with nisin at 3.2 ng ml
21 to stimulate
maximum induction (Miajlovic et al., 2007).
Manipulation of DNA. Restriction and DNA modification enzymes
were purchased from New England Biolabs or Roche Molecular
Biochemicals and were used according to the manufacturers’
instructions. DNA procedures were carried out according to standard
protocols (Sambrook et al., 1989).
Cloning and PCR amplification of Fg constructs. E. coli strains
expressing human Fg Aa-, Bb- and c-chains were provided by
Professor Susan Lord, Department of Pathology, University of
North Carolina at Chapel Hill. A 1878 bp fragment from plasmid
p166.9 (Lord, 1985) and a 1236 bp fragment from p253
(Bolyard & Lord, 1988) were subcloned into the plasmid pQE30
(Qiagen) to produce recombinant mature Aa- and c-chains with N-
terminal His tags. Subcloning of the mature recombinant Bb-chain
was described previously (Davis et al., 2001). The recombinant
plasmids were transformed into E. coli strain JM101 for protein
expression.
Segments of the Aa-chain were amplified by PCR from the plasmid
containing the full-length Aa-chain (residues 1–625 in the common
Fg a-chain, NCBI accession number AAA17055). Although Fg a-chain
DNA encodes 625 residues, in plasma the Aa-chain is only 610
residues long due to a post-translational modification. The oligonu-
cleotide primers used for PCR are listed in Table 1. Restriction sites
were incorporated at the 59 ends of the primers to facilitate
directional cloning. PCR amplification was carried out in a DNA
thermal cycler (Perkin-Elmer Cetus) with Phusion DNA-polymerase
(Bioline). Reactions were carried out with a 30 s denaturation step at
98 uC, a 10 s annealing step (the temperature of which depended on
the individual primers) and elongation at 72 uC depending on the
length of the PCR product. This standard cycle was repeated 25 times
followed by incubation at 72 uC for 10 min. PCR products were
purified using the Favourgen Gel/PCR Purification Kit (Favourgen
Biotech), cleaved with the appropriate restriction enzyme and cloned
into plasmid pQE30.
Mutagenesis of Aa-chain of Fg. Site-directed mutagenesis was
carried out on pQE30 carrying the gene encoding Aa-1–625 using
Quickchange (Stratagene). The primers used in the mutagenesis
protocol are listed in Table 1. Two mutants were created: Aa-S317P
and Aa-T322P.
Tandem repeat 5 of Aa-S317P was made to resemble repeat 3. Repeat
5o fA a-T322P resembles repeats 1 and 2, which have proline residues
in the middle of their repeat sequences.
Construction of recombinant a-chain mutants. Sections of the
Aa-chain were deleted by inverse PCR using oligonucleotide primers
Fig. 1. Structure of fibrinogen. Fg consists of two identical
disulfide-linked subunits, each of which is composed of three non-
identical polypeptide chains, Aa,B b and c. Fg can be divided into
four major regions, the central E region, two identical terminal D
regions and the aC-domains. The aC-domains (residues 221–
610) contain two distinct regions, a compact C-terminal half and
an unordered NH2-terminal half or connector region.
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and the reverse primers contained half an EcoRV site at their 59 ends,
respectively. The PCR products were digested with EcoRV, religated
and transformed into E. coli XL-1 Blue cells. Amino acid residues D
and I were inserted in place of the region of DNA that was deleted
from the aC-domain.
Sequencing of recombinant plasmids. All recombinant plasmids
were sequenced by GATC Biotech.
Expression and purification of recombinant proteins.
Recombinant rClfA 221–559, rClfB 45–542 and rClfB 197–542 were
purified by Ni
2+ affinity chromatography as described previously
(O’Connell et al., 1998; Perkins et al., 2001). Purification of the
recombinant Fg Aa-, Bb- and c-chains, and each of the recombinant
Aa-chain deletion and truncated proteins, was carried out by Ni
2+
affinity chromatography (Perkins et al., 2001) with the addition of
6 M urea (Sigma) to the bacterial cell suspension prior to lysis.
SDS-PAGE and Western immunoblotting. Recombinant proteins
were analysed by SDS-PAGE by standard procedures (Laemmli, 1970)
on gels containing 10–15% acrylamide. Gels were stained with
Coomassie blue. Human Fg (Calbiochem) was separated by SDS-
PAGE and transferred electrophoretically to PVDF Western blotting
membranes (Roche Applied Science) by the wet system (Bio-Rad) in
Tris/HCl (0.02 M), glycine (0.15 M) and methanol (20%, v/v).
Membranes were blocked for 15 h at 4 uC in 10% (v/v) non-dry fat
milk and then incubated with recombinant ClfA or rClfB
(10 mgm l
21) for 1 h with shaking. The membranes were washed
three times with PBS containing Tween 20 (0.01%, w/v) and then
incubated with polyclonal antisera to ClfA (1:2000) (McDevitt et al.,
1995) or ClfB (1:2000) (McAleese et al., 2001) as appropriate.
Horseradish peroxidase (HRP)-labelled goat anti-rabbit IgG (Dako,
1:2000) was used to detect bound antibody. Membranes were
developed using LumiGLO chemiluminescent substrate (New
England BioLabs) according to the manufacturer’s instructions and
exposed to X-ray film.
Fibrinogen. Native human Fg was from Calbiochem. Recombinant
Fg Aa251 contains Aa-chains truncated at residue 251 but is otherwise
identical to normal human Fg. It was purified from CHO cells media
(Gorkun et al., 1998). Plasmin digestion of native Fg was performed
to isolate fragment D-domains (Rudchenko et al., 1996). Briefly, Fg
(70 mg) in Tris-buffered saline (TBS) pH 7.4 was treated with
plasmin [0.0015 unit (mg Fg)
21] for 6 h at room temperature. The
reaction was stopped by the addition of phenylmethylsulfonyl
fluoride (Sigma) to 0.5 mM final concentration and dialysed
overnight at 4 uC into TBS pH 7.4. The sample was then applied to
a MonoQ HP anion-exchange column and eluted with a gradient of
0–1 M NaCl. SDS-PAGE and Western blotting with anti-Fg domain
D and anti-Fg domain E polyclonal antibodies (Cambio) showed the
D- and E-domains eluting at 250 mM and 350 mM NaCl,
respectively.
Adherence of bacteria to immobilized proteins. Adherence of S.
aureus or L. lactis to immobilized proteins was performed as
described previously (Walsh et al., 2004). Nunc-Immuno MaxiSorb
microtitre plates were coated with the protein in carbonate buffer
(15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and incubated overnight
at 4 uC. Wells were washed with PBS, BSA (5 mg ml
21) was added
and the plates were incubated for 2 h at 37 uC. The plates were
washed three times with PBS. A bacterial cell suspension (OD600 1.0
in PBS) was added (100 ml per well) and the plates were incubated for
1 h at room temperature. Plates were washed three times with PBS
and bound cells were fixed with formaldehyde (25%, v/v) for 30 min
and stained with crystal violet (0.5%, v/v 100 ml per well) for 1 min.
Following three washes with PBS, acetic acid (5%, v/v) was added
(100 ml per well) for 10 min at room temperature. The absorbance
Table 1. Synthetic oligonucleotides used to amplify Aa-chain fragments and for site-directed and deletion mutants of the a-chain
Restriction endonuclease sites are underlined. The nucleotides in boldface indicate the location of the desired mutation. F corresponds to forward
primer; R corresponds to reverse primer.
Expression constructs Primer name Primer sequence
Truncated proteins Aa-1F CGG GGA TCC GCA GAT AGT GGT GAA GGT G
Aa-232F GAC GGA TCC TTA ACA GAC ATG CCG CAG ATG AG
Aa-315F CGG GGA TCC TGG AAC TCT GGG AGC TCT GG
Aa-367F CGG GGA TCC TGG CAC TCT GAA TCT GGA AG
Aa-283R CGG AAG CTT AGG TCC AGA GCT CCC AGA GTT C
Aa-574R CGG AAG CTT TTA GTC TCC TCT GTT GTA ACT CGT G
Aa-625R CGG AAG CTT TTA GGG GGA CAG GGA AGC CTT C
Deletion mutagenesis Aa-329F GCG CTG ATA TCG GAA ACC AAA ACC CTG GGA G
Aa-341F GCG CTG ATA TCG GTA GTA CCG GAA CCT GG
Aa-344F GCG CTG ATA TCT GGA ATC CTG GCA GCT CTG
Aa-373F CGC TGA TAT CGG AAG TTT TAG GCC AGA TAG
Aa-286R ATC TCG GTT TCC AGT ACT TCC AG
Aa-315R ATC CCA GCT TCC AGT ACT TCC AG
Aa-331R ATC GTC CCC AGG GTT TTG GTT CTT
Aa-341R ATC CCA GGT TCC GGT ACT ACC AG
Site-directed mutagenesis Aa-S317PF GCTGGAACCCTGGGAGCTCTGGAAC
Aa-S317PR GTTCCAGAGCTCCCAGGGTTCCAGC
Aa-T322PF TGGGAGCTCTGGACCTGGAAGTACTGGAAAC
Aa-T322PR GTTTCCAGTACTTCCAGGTCCAGAGCTCCCA
ClfB mutant N526F GTT GGA ATA ATG AGGC T G TTG TAC GTT ATG GTG G
N526R CCA CCA TAA CGT ACA ACAG C C TCA TTA TTC CAA C
E. J. Walsh and others
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Multiskan Plus). Inhibition of bacterial adherence by rClfB 197–542
was performed as described by Perkins et al. (2001).
Binding of rClfB 45–542 to immobilized proteins. ELISA plates
were coated with the appropriate protein in carbonate buffer
overnight at 4 uC. Wells were washed twice with PBS and incubated
at 37 uC with BSA in PBS for 2 h at 37 uC. They were then washed
with PBS and varying concentrations of rClfB 45–542 in PBS with
Tween 20 (0.01%, w/v) were added. The plates were then incubated
for 1 h at room temperature. Any unbound protein was removed by
washing with PBS, and plates were incubated with rabbit anti-ClfB
45–452 antibodies for 1 h at room temperature. Wells were washed
and HRP-labelled goat anti-rabbit IgG (1:2000) was added for 1 h at
room temperature. After washing, 1 mg ml
21 tetramethylbenzidine
chromogenic substrate and 0.006% (v/v) H2O2 in 0.05 M phosphate
citrate buffer pH 5.0) was added (100 ml per well) and plates
developed for 10 min in the dark. The reaction was stopped by the
addition of 2 M H2SO4 (50 ml per well), and plates were read at
450 nm.
To check that native and mutant Fg Aa251 were coating the ELISA
plates efficiently, HRP-labelled anti-human Fg antibody (Dako
1:4000) was added to the plates following the initial blocking step.
The plates were incubated at room temperature for 1 h with shaking.
After washing with PBS, bound antibody was detected by adding
tetramethylbenzidine and H2SO4 and reading the absorbance at
450 nm.
RESULTS
ClfB binds to the a-chain of human Fg
Native whole human Fg was separated into individual Aa-,
Bb- and c-chains by denaturing SDS-PAGE, transferred to
PVDF membranes and probed with recombinant (r) ClfB
region A-domain (rClfB 45–542). Binding of rClfB was
detected with anti-ClfB region A antibodies. The rClfB
protein bound specifically to the Aa-chain (Fig. 2a). In
contrast, rClfA region A-domain rClfA 40–559 reacted with
the c-chain of human Fg (Fig. 2a), confirming previous
reports (McDevitt et al., 1997).
Purified recombinant Fg Aa-, Bb- and c- chains were
immobilized and tested for their ability to support the
adherence of ClfB-expressing S. aureus cells. The ability of
S. aureus Newman cells defective in ClfA to adhere to Fg is
exclusively due to expression of ClfB. Newman does not
express the bifunctional fibronectin- and Fg-binding
proteins FnBPA and FnBPB (Wann et al., 2000).
Newman clfA adhered to recombinant Aa-chain (rAa 1–
625) in a dose-dependent and saturable manner but did
not adhere to either the recombinant Bb-chain or the c-
chain (Fig. 2b). The double clfA clfB mutant did not adhere
to Fg or the Aa-chain (Fig. 2c). These data clearly show
that ClfB binds only to the Aa-chain of Fg and not to the
Bb-chain as was reported previously (Ni Eidhin et al.,
1998). A truncated but functional form of rClfB 197–542
(Perkins et al., 2001) inhibited adherence of Newman clfB
to rAa 1–625 in a dose-dependent manner (Fig. 3),
indicating that recombinant ClfB and ClfB expressed by
S. aureus compete for the same binding site(s).
ClfB binds to a site within the aC-domain of
human Fg
Mutant recombinant human Fg with a deletion of residues
252–625 comprising the C terminus of the Aa-chain (Fg
Aa251) was purified from CHO cells (Gorkun et al., 1998).
Native human Fg and Fg Aa251 were coated onto the wells
of a microtitre dish and tested for their ability to support
adherence of S. aureus cells and binding by rClfB protein.
S. aureus Newman clfA adhered strongly to native Fg but
Fig. 2. ClfB binds to Fg Aa-chain. (a) Ligand affinity blotting.
Human Fg was fractionated by SDS-PAGE and stained with
Coomassie blue (lane 1), or transferred to a PVDF-membrane and
probed with rClfB 45–542 (lane 2) or rClfA 220–559 (lane 3).
Binding of rClf proteins was detected with anti-Clf polyclonal
antisera. (b) Adherence of S. aureus Newman ClfA
” to immobilized
recombinant Aa-( $), Bb-( m)o rc-( .) chains of Fg. (c)
Adherence of S. aureus Newman ClfA
” (#) and Newman ClfA
”
ClfB
” ($) to immobilized recombinant Aa-chain of Fg. Cells were
grown to exponential phase and suspensions (110
8 c.f.u.) were
added to wells. Adherent bacteria were detected by crystal violet
staining. The experiment was performed twice with similar results
and values represent means±SD of triplicate wells.
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bound very weakly to Fg Aa251 in an ELISA-based assay
(Fig. 4b). Plasmin treatment of Fg cleaves the protein into
an E-fragment, two D-fragments and two aC-domains.
Purified D- and E-domains of Fg did not inhibit the
adherence of S. aureus cells to Fg (data not shown). These
data suggest that the binding site for ClfB in Fg lies in the
C-terminal region of the Aa-chain of Fg between residues
T251 and V610.
To investigate further the binding site for ClfB within the C
terminus of the Aa-chain, a series of truncated forms of the
recombinant a-chain were expressed (Fig. 5a). The proteins
were purified, immobilized in ELISA wells and tested for
their ability to support the adherence of S. aureus Newman
clfA. Bacteria adhered to the protein corresponding to the
C-terminal half of the Aa-chain (rAa 232–625) but did not
adhere to the N-terminal region (rAa 1–283, Fig. 5a),
confirming that the ClfB-binding site in the Fg a-chain is in
the C-terminal domain. The C-terminal a-chain construct
(rAa 232–625) was further truncated in order to locate the
binding site for ClfB (Fig. 5b). The truncated proteins were
tested for their ability to support the adherence of ClfB
+ S.
aureus cells. The smallest truncate that supported binding
of ClfB was rAa 315–574, whereas rAa 367–625 did not,
Fig. 3. Inhibition of S. aureus Newman ClfA
” adherence to
recombinant Aa-chain by rClfB 197–542. ELISA plates coated
with Fg rAa-chain 1–625 were incubated with increasing concen-
trations of rClfB 197–542 for 1 h at room temperature. Newman
ClfA
” cells grown to exponential phase (110
8 c.f.u.) were added
to wells and adherent bacteria were detected by crystal violet
staining. The values represent means of triplicate wells.
Fig. 4. Binding to native and mutant Fg. (a) Adherence of S.
aureus Newman ClfA
” cells to immobilized native Fg ($), or
mutant Fg Aa251 (#). Exponential-phase cells (110
8 c.f.u.) were
added to wells and adherent bacteria were detected by crystal
violet staining. (b) Binding of rClfB 45–542 to native Fg ($), or
mutant Fg Aa251 (#). The experiment was performed twice with
similar results and the values represent means±SD of triplicate
wells.
Fig. 5. Localization of the ClfB-binding site in Fg using
recombinant Aa-chain truncates. (a) Adherence of S. aureus
Newman ClfA
” to immobilized recombinant Fg Aa-chain truncates,
rAa 232–625 (X) and rAa 1–283 (%). (b) Adherence of Newman
ClfA
” to rAa 367–574 (h), rAa 367–625 (m) and rAa 315–574
(.). Increasing concentrations of recombinant a-chain constructs
were immobilized on ELISA plates and exponential-phase cells
(110
8 c.f.u.) were added to the wells. Adherent bacteria were
detected by crystal violet staining. The values represent the
means±SD of triplicate wells.
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and W367 in the aC-domain.
ClfB binds to repeat region 5 within the flexible
connector region of the Aa-chain
The structural organization of the Aa C-terminal domain
(residues 221–610) of human Fg has not yet been fully
established. It has been shown that each aC-domain consists
of two structurally distinct regions, a compact C-terminal
half connected to the rest of the molecule via an unordered
NH2-terminal connector region (Fig. 1) (Burton et al., 2006;
Tsurupa et al., 2002). In human Fg the flexible connector
region starts with a 43-residue segment followed by ten 13-
residue tandem repeats (Fig. 6) (Tsurupa et al., 2002). Using
rAa-chain truncates we located the binding site for ClfB to
betweenresidues W315and W367(Fig. 5), correspondingto
tandem repeats 5–8. Deletion mutants that had lost one or
more of the tandem repeats were created in the plasmid
expressing Aa 1–625. The ability of S. aureus ClfB
+ cells to
adhere to the recombinant mutant proteins was investigated
(Fig. 7). S. aureus cells adhered in a dose-dependent and
saturable manner both to the wild-type recombinant Aa-
chain and toanAa-chainconstructthat containeda deletion
of most of repeat 6 (Aa 1–625 D332–343). Cells also adhered
to a construct with deletion of repeats 7 and 8 (Aa 1–625
D342–372), although the binding appeared to be weaker
(Fig. 7). However, ELISA with anti-Fg antibodies showed
that rAa 1–625 D342–372 coated the plates poorly compared
to all of the other proteins (data not shown), which might
explain the lower adherence. Crucially, a deletion lacking
repeat 5 (rAa 1–625 D316–328) failed to support adherence,
suggesting that the ClfB-binding site is located in this region
of the a-chain of Fg.
Altering residues in repeat 5 of the Aa-chain
disrupts binding to ClfB
The possibility that an additional ClfB-binding site occurs
in repeats 1–3 (residues 264–302) was investigated by
Fig. 6. Schematic diagram showing the organization of the aC-domain of human Fg. (a) The unordered NH2-terminal half
(residues 221–391) is composed of a 43 amino acid segment followed by ten 13-residue tandem repeats. The recombinant
Aa-chain proteins used in this study are shown by lines and correspond to truncated or deleted variants. (b) Amino acid
sequence of the N-terminal part of the aC-domain. The ten tandem repeats begin at T264 and are shown in alternating normal
and bold type.
Clumping factor B binding to fibrinogen Aa-chain
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1–625. Purifed recombinant Aa 1–625 chain and two
mutants (S317P and T322P) were tested for their ability to
support adherence of Newman clfA. ELISA with anti-6xHis
antibody (Roche) showed that each protein coated the
microtitre plates equally well (data not shown). Newman
clfA bound to the wild-type Aa-chain in a dose-dependent
and saturable manner (Fig. 8). Newman clfA was not able to
adhere to the Aa-T322P mutant, while adherence to the Aa-
S317P mutant was reduced. The inability of Aa-T322P to
support binding to ClfB suggests that there is a single
binding site for ClfB in the a-chain of Fg located in repeat 5.
Expression of ClfB mutants by L. lactis
In order to investigate if the trench located between
domains N2 and N3 of ClfB is important in binding to the
Fg Aa-chain, several residues with side chains that were
predicted to be located close to or within the trench were
converted to alanine and expressed on the surface of L.
lactis NZ9800 from the nisin-inducible vector pNZ8037. L.
lactis-expressing mutants Q235A and N256A were defective
in adherence to immobilized Fg (Fig. 9) and CK10 (data
not shown) compared to the wild-type control. Western
immunoblotting indicated that the proteins were expressed
at the same level as the wild-type and were intact. This
suggests that CK10 and Fg likely bind to the same region of
ClfB.
Fig. 7. Localization of the ClfB-binding site in
the tandem repeat region of the aC-domain of
Fg using recombinant Aa-chain deletions.
Increasing concentrations of recombinant a-
chain constructs were immobilized on ELISA
plates. Exponential-phase Newman ClfA
” cells
(110
8 c.f.u.) were added to the wells and
adherent bacteria were detected by staining
with crystal violet. Error bars represent stand-
ard deviations for three replicates. The experi-
ment was performed twice with similar results.
Fig. 8. Adherence of S. aureus Newman ClfA
” cells to
immobilized recombinant Fg Aa-( $), AaS317P- (#) and Aa-
T322P- (m) chains. Increasing concentrations of recombinant a-
chain constructs were immobilized on ELISA plates. Exponential-
phase Newman ClfA
” cells (110
8 c.f.u.) were added to the wells
and adherent bacteria were detected by staining with crystal violet.
Bars represent standard deviations for three replicates. The
experiment was performed twice with similar results.
Fig. 9. Fg binding by L. lactis ClfB
+ and L. lactis ClfB mutants. L.
lactis ClfB
+ (m), L. lactis ClfB Q235A (#), L. lactis ClfB N526A
($) and L. lactis pNZ8037 (h) were induced with nisin and grown
to stationary phase. Adherence of washed cultures to ELISA plates
coated with Fg (10 mgm l
”1) was assessed by crystal violet
staining; the values represent the means±SD of triplicate wells.
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Many aspects of haemostasis and wound healing involve
the aC-domains of Fg playing a central role. The two self-
interacting aC-domains are formed by the C-terminal two-
thirds of the two Aa-chains (residues 220–610) (Burton
et al., 2006; Medved et al., 1983). Compared to the rest of
the Fg molecule, the aC-domains are very sensitive to
proteases and are readily cleaved into smaller fragments
(Doolittle, 1984; Henschen & MCDonagh, 1986; Weisel &
Medved, 2001), and they are the first portions of fibrin to
be removed upon fibrinolysis (Tsurupa & Medved, 2001).
This paper presents data that define the binding site in Fg
for ClfB as being located in repeat 5 of the flexible region of
the Aa-chain. Only the Aa-chain and not the Bb-o rc-
chains could support binding of ClfB. Fg with a deletion of
the entire aC region and a recombinant Aa-chain mutant
lacking the C-terminal aC region did not support binding.
A series of recombinant truncated proteins narrowed down
a binding domain to repeat 5 located between residues 316
and 328.
In human Fg each individual tandem repeat is composed of
13 amino acids (Fig. 6). Up to eight residues in the repeats
are glycine or serine. Repeat 5 (NSGSSGTGSTGNQ) may
form a loop similar to the Tyr-(Gly/Ser)n V loops present
in the tail region of CK10, to which ClfB also binds (Walsh
et al., 2004). Since the repeats that apparently do not
support ClfB binding contain proline and/or arginine
residues (Fig. 6), it is possible that these residues interfere
with the potential of ClfB to bind to other parts of the
repeat region. To examine this, two mutants in repeat 5
mimicking the presence of proline residues located in other
putative non-ClfB-binding repeats were isolated in a
recombinant Fg a-chain construct that contained each of
repeats 1–8. The S317P mutant had reduced affinity for
ClfB whereas the T322P mutant was unable to bind ClfB.
This suggests that repeat 5 is the only site in the Fg a-chain
that ClFB binds to, and that T322 is crucially important for
this. The presence of a P in the centre of the putative V
loops in other repeats, in particular repeat 2, might explain
their apparent inability to support binding in the T322
mutant. The S317P substitution creates a sequence in
repeat 5 that resembles repeat 3. It is unclear why wild-type
repeat 3 did not support reduced ClfB binding in the S317
mutant similar to the T322P substitution in repeat 5.
Perhaps the sequences at the C terminus of repeat 3 that
differ from repeat 5 are responsible.
This study suggests that Fg and CK10 have the same or
overlapping binding sites on ClfB (Walsh et al., 2004) and
that the mechanism of ClfB binding to Fg is likely to be
similar to K10 binding. Amino acid substitution mutants
Q235A and N256A located in the putative binding trench
in ClfB between domains N2 and N3 were defective in
binding to both Fg and CK10.
A common theme is emerging concerning the nature of
ligands recognized by surface proteins of staphylococci of
the Clf-Sdr family. Each binds flexible unfolded peptides,
with ClfA and FnBPA binding to the short flexible c-chain
C-terminal peptide that protrudes from domain D of Fg
(McDevitt et al., 1997) while SdrG binds to peptides at the
N-terminal end of the b-chain that extend from domain E
(Davis et al., 2001; Ponnuraj et al., 2003). ClfB binds to
glycine- and serine-rich loops at the C terminus of CK10
(Walsh et al., 2004) and this study reveals that ClfB also
binds to the flexible connector region of the aC region of
Fg. It is logical to postulate that each of these MSCRAMMs
binds their ligand(s) by the dock latch and lock mechanism
(Ponnuraj et al., 2003) but this can only be shown for
certain by solving the X-ray crystal structure of the
MSCRAMM with the ligands bound.
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